Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04340050 · ClinicalTrials.gov registry record · Early Phase 1
COVID-19 Convalescent Plasma
A Early Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT04340050 is a Early Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 10 participants.
The verdict
NCT04340050, a Early Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the feasibility of delivering anti-SARS-CoV-2 convalescent plasma to hospitalized patients with severe or life-threatening COVID-19. Beyond supportive care, there are currently no proven treatment options for coronavirus disease (COVID-19), the infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Human convalescent plasma is an option for treatment of COVID-19 and could be rapidly available when there are sufficient numbers of people who have recovered and can donate high titer neutralizing immunoglobulin-containing plasma. Hypothesis: Collecting and administering convalescent plasma requires a level of logistical coordination that is not available in all centers. Objective: To establish feasibility for a hospital-based integrated system to collect and administer convalescent plasma to patients with severe or life-threatening COVID-19.
Interventions
- BIOLOGICAL anti-SARS-CoV-2 convalescent plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-04-10 |
| Est. Completion | 2020-12-23 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04340050
The ClinicalTrials.gov registry entry for NCT04340050 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which anti-SARS-CoV-2 convalescent plasma is the first listed.
NCT04340050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04340050 about?
NCT04340050 is a clinical study titled "COVID-19 Convalescent Plasma". The purpose of this study is to assess the feasibility of delivering anti-SARS-CoV-2 convalescent plasma to hospitalized patients with severe or life-threatening COVID-19. Beyond supportive care, there are currently no proven treatment options for coronavirus disease (COVID-19), the infection cause...
What is the current status of trial NCT04340050?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2020-04-10. Estimated completion is 2020-12-23.
What interventions are being tested in trial NCT04340050?
The interventions under investigation include: anti-SARS-CoV-2 convalescent plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04340050?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.